They are developing innovative therapeutic strategies to treat HER2 positive tumours and to identify mechanisms of resistance to current treatments. Working on the characterisation of the role of premature senescence in the progression and treatment of breast cancer, and the study of the implications of the immune system for the progression of cancer.

Among other strategic objectives is the evaluation of the activity of innovative therapeutic strategies in our sets of xenografts deriving from breast and pancreatic cancer patients. And the continued development of a research programme into pancreatic cancer in close collaboration with the clinical research programme run by the Vall d'Hebron Institute of Oncology (VHIO), led by Josep Tabernero. 

Visit the research group’s page

Ponderació
9

Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vhebron.net, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.